30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 21 Clinical Trial Design Nuances for Psychedelic Therapies

This podcast episode explores the complex challenges of designing clinical trials for psychedelic therapies, particularly focusing on unique issues like the placebo effect and functional unblinding. The discussion covers how researchers use active placebos and creative trial designs to control for expectation bias. It also examines the FDA's stance on regulating psychedelic therapy, highlighting the complex relationship between drug approval and therapeutic context. The episode emphasizes the importance of standardized therapy protocols while maintaining flexibility for individual experiences.